Takeda announces senior appointment

James Morley takes over as general manager at Chemistry, Manufacturing and Controls Centre

James Morley has been promoted to general manager at Takeda’s Chemistry, Manufacturing and Controls Centre. He was previously VP of the Japanese pharmaceutical firm’s Global Research & Development Centre.

You may also like

Pharmaceutical
Takeda and Innovent Biologics partner to advance next-gen oncology medicines

Takeda and Innovent Biologics partner to advance next-gen oncology medicines

Takeda will establish manufacturing of two next-generation late-stage investigational medicines in the US and will receive exclusive commercialisation rights for IBI363 and IBI343 outside the US and China
Manufacturing
Future thoughts about pharmaceutical manufacturing

Future thoughts about pharmaceutical manufacturing

COPA-DATA's Giuseppe Menin and his colleagues from an ISPE working group discuss shifting from a systems to a service-oriented architecture
Research & Development
Evox Therapeutics and Takeda sign multitarget rare disease collaboration

Evox Therapeutics and Takeda sign multitarget rare disease collaboration

Collaboration focuses on developing novel protein replacement and mRNA therapies and explores the targeted delivery of these payloads using Evox’s proprietary exosome technology
Finance
Charles River secures milestone deals with Takeda and HemaCare

Charles River secures milestone deals with Takeda and HemaCare

The laboratory giant inks deal with global Japanese drugmaker and completes acquisition of the cell and gene products manufacturer
Design & Build
Takeda opens first API facility in Ireland

Takeda opens first API facility in Ireland

The Japan-based group is also investing $33.5m in what will be the first commercial scale cell-therapy production facility in Ireland
Research & Development
Takeda opens new drug research facility in California

Takeda opens new drug research facility in California

The 165,000 sqft facility will play an important role in connecting research collaborators from a local to a global scale
Media
Only a handful of pharma companies are developing the urgently needed new medicines for the poor

Only a handful of pharma companies are developing the urgently needed new medicines for the poor

The development of new medical products that are considered the highest priority for people in developing countries is highly concentrated – among five pharmaceutical companies and on five diseases
Subscribe now